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Miriam Sirianni, Caterina La Cascia, Simona A. Stilo, Tiago Reis Marques, Rowena Handley,
Valeria Mondelli, Paola Dazzan, Carmine Pariante, Anthony S. David, Craig Morgan, John Powell, and
Robin M. Murray
Background: Cannabis use is associated with an increased risk of psychosis. One study has suggested that genetic variation in the AKT1
gene might influence this effect.
Methods: In a case-control study of 489 first-episode psychosis patients and 278 control subjects, we investigated the interaction between
variation at the AKT1 rs2494732 single nucleotide polymorphism and cannabis use in increasing the risk of psychosis.
Results: The rs2494732 locuswasnot associatedwith an increased risk of apsychotic disorder,with lifetime cannabis use, orwith frequency
of use. We did, however, find that the effect of lifetime cannabis use on risk of psychosis was significantly influenced by the rs2494732 locus
(likelihood ratio statistic for the interaction 8.54; p .014). Carriers of the C/C genotype with a history of cannabis use showed a greater
han twofold increased likelihoodof a psychotic disorder (odds ratio 2.18 [95%confidence interval: 1.12, 4.31])when comparedwith users
howere T/T carriers. Moreover, the interaction between the rs2494732 genotype and frequency of use was also significant at the 5% level
likelihood ratio 13.39; p .010). Among daily users, C/C carriers demonstrated a sevenfold increase in the odds of psychosis compared
with T/T carriers (odds ratio 7.23 [95% confidence interval: 1.37, 38.12]).
Conclusions: Our findings provide strong support for the initial report that genetic variation at rs2494732 of AKT1 influences the risk of
developing a psychotic disorder in cannabis users.v
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C annabis is the most commonly used illicit drug in the world(1).Most peoplewhouse it come tonoharm.However, it hasbecome apparent in recent years that cannabis use is a risk
factor for the development of schizophrenia-like psychotic disor-
ders (2,3). Why certain individuals develop psychosis when their
peers, who smoke similar amounts of cannabis, remain well is un-
clear. One suggestion is that such individuals may carry some ge-
netic susceptibility (4,5). Should the genes underlying such suscep-
tibility be identified, this would be of considerable public health
importance.
One candidate for a gene  cannabis interaction is the AKT1
ene, which has been associated with schizophrenia in some but
ot all studies (6–8). The AKT1 gene is an attractive candidate
ecause it codes for a protein kinase that forms an integral part of
he dopamine receptor signaling cascade in the striatum (9). More-
ver, in vivo administration to mice of delta-9-tetrahydrocannabi-
ol (delta-9-TCH), the active ingredient in cannabis, activates this
ignaling cascade via AKT1 phosphorylation (10,11). Furthermore,
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http://dx.doi.org/10.1016/j.biopsych.2012.06.020an Winkel et al. (12) studied 801 patients with schizophrenia and
40 of their siblings and reported that subjects who carried two
opies of the C allele of the rs2494732 polymorphism of the AKT1
ene were especially at risk of schizophrenia and schizotypy, re-
pectively, if they used cannabis. In a separate study, van Winkel et
l. (13) also reported an AKT1-cannabis interaction on cognitive
erformance. Among psychotic patients who used cannabis, carri-
rs of theAKT1 rs2494732C/Cgenotypedid significantlyworse on a
est of sustained attention compared with T/T carriers (13). More-
ver, a neuroimaging study showed that healthy subjects carrying
he dopamine transporter 9-repeat and the AKT1 rs130233 G/G
enotype had the greatest psychotic response and striatal activa-
ion following administration of delta-9-THC (14).
A recent critical review of gene environment (G E) research
n psychiatry concluded that direct replications deserve more at-
ention than novel findings or indirect replications (15). We there-
ore set out to directly test the veracity of the AKT1 rs2494732 
annabis interaction in a sample of patients with their first episode
f psychosis and healthy control subjects in south London. Because
f this a priori hypothesis, rs2494732was the only locus genotyped
nd tested for interaction with cannabis use.
ethods andMaterials
articipants
Participants were part of the Genetic and Psychotic Disorders
tudy case-control project that approached all patients aged 18 to
5 years who presented with their first episode of psychosis to the
ambeth, Southwark, and Croydon adult inpatient units of the
outh London and Maudsley National Health Service Foundation
rust between December 2005 and October 2010. Patients who
et ICD-10 criteria for a diagnosis of nonorganic psychosis (F20–
29 and F30–F33) (16), validated by administering the Schedules
or Clinical Assessment in Neuropsychiatry (17), were invited to
articipate in the study. Of the total approached (734), 20% (145)
BIOL PSYCHIATRY 2012;72:811–816
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812 BIOL PSYCHIATRY 2012;72:811–816 M. Di Forti et al.refused to participate and 596 patients experiencing their first epi-
sode of psychosis were successfully recruited into the study. The
twomost common reasons for refusal were a lack of interest in the
research and the length of the full assessment.
Over the same time frame, from the area served by the same
mental health units, we recruited a sample of 333 healthy control
subjects, aged 18 to 65 years, whichwas broadly similar to the local
population in terms of ethnicity, educational attainment, and em-
ployment status (18), using internet and newspaper advertise-
ments and distribution of leaflets at train stations, shops, and job
centers. None of the material used for advertising mentioned can-
nabis or illicit drug use. Volunteers willing to take part in the study
were administered the Psychosis Screening Questionnaire (19) and
were excluded if theymet criteria for a psychotic disorder or if they
reported a previous diagnosis of psychotic illness.
Further details on the agedistribution of the samples andon the
diagnostic breakdownof the cases are available in Tables S1 and S2
in Supplement 1.
The data presented in this study are based on the 489 first-
episode psychosis patients (82% of the total recruited) and 278
control subjects (83%of the total recruited) onwhomwewere able
toobtainboth ahistory concerning cannabis use andDNAsamples.
General Assessment and Data on Exposure of Interest
Sociodemographic data (age, gender, self-reported ethnicity,
level of education attainment, and employment status) on cases
and control subjects were collected using the Medical Research
Council Social Scale (20). Participants were asked if they had ever
smoked tobacco, and if theydrankalcohol, theirweekly alcohol unit
consumption was recorded. A detailed history of illicit drug use
(cannabis, stimulants, and any other recreational drug) was taken
using the Cannabis Experience Questionnaire modified version
(21). The twomeasures of exposure to cannabis use included in the
analyses were: 1) lifetime history of cannabis use, i.e., had the sub-
ject ever used cannabis at anypoint in the lifetime (No0; Yes1);
and 2) lifetime frequency of cannabis use, i.e., the frequency that
characterized the subject’s most consistent pattern of use (No 0;
at weekends or less frequently 1; everyday 2).
enotyping
DNA was obtained from all participants that completed the
ssessment described above (489 cases and 278 control subjects).
eventy-five percent of DNA samples used originated from blood
nd 25% from cheek swabs. DNA extraction was performed using
tandard phenol-chloroformmethods.
As the purpose of the study was to explicitly test for interaction
t a specific sitewithinAKT1,genotyping focused exclusively on the
an Winkel single nucleotide polymorphism (SNP), rs2494732. Off
he shelf Taqmanassays for this polymorphismare available as a kit,
t http://www.appliedbiosystems.com. The specific assay format
sed can be identified by inputting the corresponding assay ID
C_16191608_10). Genotype calls were discriminated based on al-
orithmic membership of three clusters representing homozygote
/T, heterozygote C/T, and homozygote C/C genotype classes. A
omparison of genotype results for 360 individuals with overlap-
ing blood and cheek swab DNA revealed there was 100% concor-
ance between blood- and cheek-derived genotype data.
alidation of Self-report of Ethnicity
To confirm self-report of ethnicity, genetic ancestry was derived
sing a panel of 57 ancestry informative genetic markers. These
ere genotyped using iPLEX technology developed for theMassArray
latform (Sequenom Inc., San Diego, California). Further infor-
F
C
www.sobp.org/journalation on the makeup of the marker panel is available on request.
ncestry scores were derived using the program Structure (22) to
mplement a model-based (Markov Chain Monte Carlo) clustering
lgorithm. Having determined the best solution for K (the probable
rue number of underlying genetic groups) in initial analyses, indi-
iduals who scored between 96% and 100% for genetic cluster
embership were used to create a three-way ancestral axis based
n Black African (n 81), European Caucasian (n 118), and Asian
n  16) ancestry. These reference groups were used to index ge-
etic ancestry for the remaining sample (Figure 1). Eighty-three
ercent of participants had information on both self-reported eth-
icity andancestrymarkers. Using95%todefine the cutoff point for
luster membership resulted in the genetic validation of 241 self-
eported ethnicities. The level of overall agreement between self-
eported and genetic ethnicities (96%) was reassuringly high.
thics
This study was part of the GAP study, which was granted ethical
pproval by the South London and Maudsley and Institute of Psy-
hiatry Local Research Ethics Committee. All cases and control sub-
ects included in the study gave informed written consent, signing
he consent document, to the publication of data originating from
he study.
ata Analysis
Datawere recorded in SPSS version 15 and analyzed using Stata
1 (Stata, College Station, Texas). Based on the existing literature, a
istory of 1) ever having used cannabis (referred to hereafter as
ifetime cannabis use) and 2) lifetime frequency of use were the
ain environmental measures of interest. These were analyzed in
onjunction with rs2494732. Genotypes at this locus were coded
for initial tests of main effects) to reflect the allele dosage of the
NP of interest selected in accordance with the original report (12):
/T  0; C/T  1; C/C  2. Additional sociodemographic and life-
tyle variables (such as ethnicity and other substancemisuse) were
odeled as potential confounders. Chi-square tests and t tests (or
he nonparametric equivalent of these, the Mann-Whitney U test)
ere used to test for association between potential confounders
nd both presence of psychotic disorder and genotype. Further, 2
ests were used to determine whether exposures of interest were
0
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M. Di Forti et al. BIOL PSYCHIATRY 2012;72:811–816 813associated with AKT1 genotype in control subjects (a signature of
gene environment correlation).
Finally, a logistic regression was used to test for association of
candidate genotype and presence of a psychotic disorder after
adjusting for various covariates (e.g., gender, ethnicity, and tobacco
use), along with either history of lifetime cannabis use or lifetime
frequency of use. Analyses were run separately for each exposure
and then including an interaction term between the exposure and
genotype. The interaction model used examined whether the rela-
tionship between AKT1 rs2494732 genotype and presence of psy-
chosis differed as a function of having a history of cannabis use and
also explored the possibility of a relationshipwith frequency of use.
Odds ratios (OR) of psychosis among carriers of the AKT1
s2494732 C/T and C/C genotypes compared with the T/T geno-
ype, among people with different exposures to cannabis, were
alculated from the estimates provided by the model.
Results
The sample consisted of 489 first episode of psychosis cases
(FEP) and278control subjects. First episodeofpsychosis caseswere
significantly younger (mean age 27.7 years; SD 8.4) than control
subjects (mean age 30.2 years; SD 9.5; p  .001) and, as expected,
had a mean premorbid IQ of 6.1 points lower (p  .0001). First
pisode of psychosis patientswere alsomore likely to belong to the
lack African/Caribbean group (p  .001) than control subjects
Table 1).
WeobtainedAKT1 rs2494732genotypingdataon485of 489FEP
nd on 276 of 278 control subjects, with an overall call rate of 99%.
e found no significant difference in AKT1 rs2494732 allelic distri-
ution by gender (2 4.12; p .128) or between FEP and control
Table 1. Demographic Characteristics of First Episode Psychosis Patients
nd Control Subjects
FEP
n 489
Mean (SD)
Control
Subjects
n 278
Mean (SD) dfa p Valueb
Agec 27.67 (8.4) 30.20 (9.5) Z 3.65b .001
Premorbid IQc 90.02 (10.1) 98.60 (9.6) 208 .001
n (%) n (%)
Gender
Male 322 (66.1) 165 (59.8)
Female 165 (33.9) 111 (40.2) 1 .080
No details 2 2
Self-Reported
Ethnicity
White Caucasian 152 (32.3) 146 (54.7)
Black Caribbean 157 (33.3) 53 (19.9) 3 .001
Black African 113 (24.0) 31 (11.2)
Asian/other 49 (10.4) 39 (14.2)
No details 18 9
AKT1 rs2494732
Allelic
Frequency
T/T 131 (27.0) 84 (30.4)
C/T 238 (49.1) 133 (48.2) 2 .535
C/C 116 (23.9) 59 (21.4)
No details 4 2
FEP, first episode psychosis patients.
aDegrees of freedom.
bp values from t tests (or Mann-Whitney U test) and 2 tests.
cc
Missing data: 170 control subjects and 380 cases have no premorbid IQ
information.ubjects (2 1.25; p .535). In addition,we foundnodifference in
he frequency of the AKT1 rs2494732 polymorphism across ethnic
roups (2 3.01; p .87). Genotypes at rs2494732were in Hardy-
einberg equilibrium within ethnically stratified control subjects
p .639).
rug Consumption
More than two thirds (68.6%) of the FEP patients had a history of
moking tobacco compared with 46.8% of the control subjects
2 9.3; p .001). However, the two groups did not differ in the
umber of alcohol units consumed weekly (2 6.4; p .095), the
revalence of life time cannabis use (2 .3;p .567), or on theuse
f stimulant drugs (2  2.1; p  .146). The proportion of FEP
36.2%) who reported current cannabis use was slightly, but non-
ignificantly, higher (2  3.0; p  .085) than control subjects
27.1%). We measured the reliability of the self-reported data on
urrent user status in a random sample of 56 cases, carrying out a
rinary drug screening.Of the 56 cases tested, 34had reported they
ere not current users; 32 of these (88%) had a negative urinary
rug screening; only 2 tested positive and these were excluded
rom the analyses.
Among those who had a history of lifetime cannabis use, FEP
ere more likely than control subjects to be male (2  11.8; p 
001), to be younger (mean age 26.9 years, SD 7.8 vs. mean age 29.7
ears, SD 8.6; t  3.1; p  .001), and to report daily use (73.9% vs.
9.5%; 2 35.8; p .001) (Table 2).
ase-Control G E Analyses
There was no evidence of a correlation between the AKT1
s2494732 genotype and lifetime cannabis use (2 .7, p .692) or
ifetime frequency of use (2 4.4; p .352).
A multivariable logistic regression adjusting for gender, ethnic-
ty, and tobacco use (n  598) showed a significant interaction
etween lifetime cannabis use and genotype (likelihood ratio
est  8.54; p  .014). This suggests that the effect of lifetime
able 2. Patterns of Drug Use in First Episode Psychosis Patients and
ontrol Subjects
FEP 489
n (%)
Control
Subjects 278
n (%) df p Valuea
ver Used Tobacco
No 125 (31.4) 127 (53.2) 1
Yes 271 (68.6) 112 (46.8) .001
No details 93 39
ver Used Other
Stimulants
No 201 (66.6) 157 (72.6) 1
Yes 102 (33.4) 60 (27.4) .146
No details 186 61
ver Used Cannabis
No 180 (39.3) 94 (37.1) 1
Yes 275 (60.7) 160 (62.9) .567
No details 34 24
ifetime Frequency of
Cannabis Use
Among Users
At weekends or less 50 (26.1) 73 (60.5) 1
Everyday 138 (73.9) 48 (39.5) .001
No details 90 39
FEP, first episode psychosis patients.
ap values from 2 tests.annabis use on the likelihood of suffering from a psychotic disor-
www.sobp.org/journal
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814 BIOL PSYCHIATRY 2012;72:811–816 M. Di Forti et al.der differed according to rs2494732 genotype. Among those who
had never used cannabis, there was no significant change in risk
associated with rs2494732 genotype. In contrast, among subjects
having a lifetime history of cannabis use, carriers of the C/C geno-
type showed a greater than twofold increased odds of having psy-
chotic disorder (OR  2.18; 95% confidence interval: 1.10, 4.31)
when compared with T/T carriers (Figure 2; Table 3).
In a second logistic regression, which again controlled for the
same covariates as above (n  511), we found the interaction be-
tween the AKT1 rs2494732 genotype and lifetime frequency of
cannabis use to be significant at greater than the 5% level (likeli-
hood ratio test 13.39; p .010). Among subjects who had never
used cannabis, there was again no significant association between
genotype and presence of a psychotic disorder. In contrast, among
both occasional and daily cannabis users, the OR for C/C carriers
indicated an increase in the probability of suffering a psychotic
disorder in comparison with those with the T/T genotype, but only
among daily cannabis users did the increased odds of psychosis
shown by C/C carriers reach significance (OR  7.23; 95% confi-
dence interval: 1.37, 38.12) (Figure 3; Table 4).
Discussion
Although only a minority of cannabis users ever develop a psy-
chotic disorder, its widespread use means that it is important to
establish why some individuals develop the illness. Our previous
study showed that the risk of psychosis depends, in part, on how
frequently people use cannabis (23). Our present findings confirm
the recent report of the role played by the variation at the
rs2494732 locus of AKT1 in influencing the risk of cannabis use in
causing psychosis (12). This opens up the possibility of identifying
those who should avoid the use of cannabis.
0
0.5
1
1.5
2
2.5
AKT1(T/T) AKT1(C/T) AKT1(C/C)
OR
Never used cannabis
History of Cannabis use
Figure 2.Odds ratio (OR) of psychosis for subjects with AKT1 rs 2494732 C/T
r C/C genotype compared to T/T, according to their cannabis use.
able 3. Odds Ratio of Psychosis Among Cannabis Users with C/T or C/C
enotype Compared with T/T
AKT1 rs249432 Genotype Variants Adjusted ORa 95% CI p Value
/T 1 —
/T 1.15 .67, 1.96 .616
/C 2.18 1.10, 4.31 .025m
CI, confidence interval; OR, odds ratio.
aAdjusted for gender, ethnicity, and tobacco use.
www.sobp.org/journalThe biology of cannabis-induced psychosis is only partly under-
tood (24). The active ingredient of cannabis, delta-9-TCH, is re-
ponsible for its psychotomimetic effects. Delta-9-tetrahydrocan-
abinol inhibits, via cannabinoid receptor type 1 activation, the
elease of glutamate onto gamma-aminobutyric acidergic neurons
hat project from the nucleus accumbens to the ventral tegmental
rea. These neurons normally exert an inhibitory effect on the firing
f dopamine neurons that project back to the nucleus accumbens
25). Thus, their inhibition causes increaseddopamine release in the
triatum, which is implicated in the pathogenesis of psychotic
ymptoms (26,27).
It seems logical to attempt to explain differences in the individ-
al response to the psychotogenic effects of cannabis in terms of
ndividual genetic makeup, particularly the subset of genes in-
olved in dopamine pathways. However, an early report that varia-
ion at the COMT gene might play a role remains controversial
4,28).
Nevertheless, genes that regulate signaling pathways and im-
act on dopamine transmission may still be plausible candidates
or such a G E interaction. For instance, the protein encoded by
he gene AKT1 is a serine/threonine kinase, whose main function is
he phosphorylation and consequent inactivation of glycogen syn-
hase kinase (GSK-3) (26). AKT1 and GSK-3 are known to be at the
eart of a signal transduction framework, initiated by dopamineD2
ignaling, which ultimately influences a wide range of cellular pro-
esses, including apoptosis, cell survival, and metabolism (29). A
ecent neuroimaging study by Blasi et al. (30) showed that AKT1/
RD2 polymorphisms are epistatically associated with attentional
rocessing and response to olanzapine treatment in schizophrenia.
hese findings further support the role of the AKT1 pathway in
egulating D2 receptor dependent dopamine signaling and its role
n psychotic disorders.
Moreover, in vivo studies have reported that delta-9-THC can
nduce phosphorylation of AKT1 with its activation in several brain
reas, including the striatum (31). As the activation of the AKT1/
SK-3 cascade is known to impact onD2 receptor signaling (32,33),
t is plausible that delta-9-THC might increase liability to psychosis
ia this pathway. Our findings need to be considered in light of
ome potential limitations.
First, it is possible that our method of control subject recruit-
0
1
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3
4
5
6
7
8
AKT1(T/T) AKT1(C/T) AKT1(C/C)
OR
Never used cannabis 
Used cannabis at week ends or less
Used cannabis everyday
igure3.Odds ratio (OR) of psychosis forAKT1 rs 2494732C/T or C/C carriers
ompared to subjects with the T/T genotype depending on lifetime fre-
uency of cannabis use.ent could have biased our findings. However, there is no sugges-
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M. Di Forti et al. BIOL PSYCHIATRY 2012;72:811–816 815tion that we undersampled cannabis users. Indeed, the proportion
of control subjects that had ever used cannabis (63%) was higher
than the national average (47%) for similar age groups. This is
probably a reflectionof thehigherprevalenceof cannabisuse in the
local community compared with the United Kingdom as a whole
(34). Almost equal prevalenceof exposure in both cases and control
subjects increases thepowerofGEanalyses. It is possible that our
control subject recruitment strategy biased our sample toward one
of mild cannabis users. Our advertising strategy included internet
and local newspapers ads, as well as distribution of leaflets at local
shops, job centers, and community centers. There is no evidence
that such methods of advertising are more likely to bias toward
better functioning and socially adjusted subjects; indeed, the op-
posite might happen. Therefore, it seems unlikely that the differ-
ence in frequency of cannabis use by cases and control subjects is
driven by a recruitment bias.
Second, our sample is multiethnic. This could be limiting, given
that HapMap reports the following differences in allele frequency
betweenpopulations: BlackAfrican: .42,White Caucasian: .46, Asian
(Chinese and Japanese): .62 (35). To account for the possibility of
population stratification, we controlled for the potential confound-
ing effect of ethnicity. However (as already reported), we could find
no actual difference between the frequency of rs2494732 alleles
across themain (black andwhite caucasian) ethnic groups (in cases
and control subjects) (Table 5). This is consistent with HapMap data
and the marginal difference between the minor allele frequency
estimates themselves in African and Caucasian populations (.42 vs.
.46), compared with Chinese and Japanese. Our sample comprised
just three cases and two control subjects of Chinese and Japanese
origin. Thus, latent differences in allele frequency at rs2494732
were very unlikely to have biased the outcome of the study.
Another possible limitation is the lack of evidence that variation
at the locus of our AKT1 SNP of interest (rs2494732) affects the
signaling pathway. There are no available data describing if and
how changes in the AKT1 genotype for rs2494732 impact on the
protein function. Nevertheless, HapMap 3 preliminary data report
(36) that rs2494732 is 702 base pairs apart from rs1130233, a SNP
that has been shown to affect AKTgenemessenger RNAexpression
(37). The R2 (a measure of correlation) between these two SNPs
Table 4. Odds Ratio of Psychosis for C/T or C/C Carriers Compared with Sub
Cannabis Use
AKT1 rs249432
Genotype
Variants
Never Used Used C
Adjusted ORa 95% CI p Value Adjusted
T/T 1 — 1
C/T .80 .39, 1.62 .532 1.04
C/C .53 .24, 1.16 .114 .86
CI, confidence interval; OR, odds ratio.
aAdjusted for gender, ethnicity, and tobacco use.
Table 5. This Shows No Significant Difference in the AKT1 rs2494732 Allelic
Ethnicity
AKT1 rs2494732 Genotype Frequency in Cont
Subjects (n 265) (%)
T/T C/T C/
White Caucasian 49 (34) 71 (49) 25 (
lack Caribbean 14 (26) 27 (51) 12 (
lack African 4 (13) 18 (60) 8 (
sian/Others 15 (40) 11 (30) 11 (ap values from 2 test.rs2494732 and rs1130233) is .95,whichgenetically speaking is very
igh and suggestive of linkage dysequilibrium. This might explain
hy the studies that have tested for an AKT1-cannabis interaction
n either a psychosis outcome (12,14) or altered cognitive perfor-
ance (13) have converged in the same direction whether select-
ng rs2494732 or rs1130233 as the genetic variant of interest.
Finally, we relied on self-report concerning cannabis use. We
id, however, check the urine of a subsample and found concor-
ance of the two methods in a very high proportion of cases. Fur-
hermore, any inaccuracy would have diminished our likelihood of
nding an interaction effect.
The main strength of our study is its design. A case-control
trategy is the gold standard design to test G  E interaction hy-
otheses (38). In addition, in keeping with good methodological
ractice for a G E replication study (39), we genotyped only the
andidate genetic variant and selected the environmental expo-
ure according to the priori hypothesis suggested by the original
eport (12) we set to replicate; thus, we avoided multiple testing.
Our study sample size had 70% power to detect, at a 5% signifi-
ance level, the twofold increased likelihood of psychotic disorder
n AKT1 rs2494732 C/C carriers with history of cannabis use com-
ared with T/T carriers. Importantly, it had over 80% power to
etect the sevenfold increase in OR we report in AKT1 rs2494732
/C carrierswhousedcannabisdaily comparedwith theT/Tones. In
he original report, van Winkel et al. (12) also noted a significant
nteraction between frequency of use, as a measure of exposure to
annabis, and AKT1 rs2494732, which further indicates that our
esults are a true replication.
In conclusion, our findings confirm the moderating role of the
KT1 rs2494732 C/C genotype on the effect of cannabis use in
ncreasing the risk of a psychotic disorder.
Nevertheless, genome-wide association studies have shown
hat the term polygenic can refer to hundreds or thousands of
ommon variants (40). Therefore, it is likely that AKT1 rs2494732
ontributes to susceptibility to the psychotogenic effect of canna-
is together with other genetic variants. Indeed, a recent report
hows that five of the novel schizophrenia loci identified by the
chizophrenia Psychiatric Genome-Wide Association Study Con-
ortium impact on the AKT pathway and concludes that these
with the T/T Genotype Depending on Their Lifetime Frequency of
bis at Weekends or Less Used Cannabis Every Day
95% CI p Value Adjusted ORa 95% CI p Value
— 1 —
.41, 2.66 .928 .87 .36, 2.12 .766
.26, 2.80 .803 7.23 1.37, 38.12 .020
ibutions by Ethnicity in Control Group
Allelic Frequency
Hardy-Weinberg
p ValueaT C
169 (.58) 121 (.42) Nonsignificant
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816 BIOL PSYCHIATRY 2012;72:811–816 M. Di Forti et al.genesmay be involved in “converting information from theenviron-
ment to this biological system” (8). Identifying such gene variants and
the biological pathways they influence can improve our understand-
ingonhow they exert their effect on an individual’s liability topsycho-
sis in the presence of particular environmental risk factors. This should
help us to design health, educational, and screening campaigns tai-
lored to reach those groups at particular risk.
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